drugset
Drugs / TORL-2-307-ADC
last change Jun 2026 re-read 3 minutes ago

TORL-2-307-ADC

also known as CLDN18.2-307-ADC

Other / unclassified targets CLDN18

Developed for
gastric cancer · gastroesophageal junction adenocarcinoma · malignant pancreatic neoplasm
Investigated by
TORL Biotherapeutics, LLC · Translational Research in Oncology

Trials 1

today NCT05156866 · Ph 1
20222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT05156866 Feb 2022 → Jun 2026 overdue gastric cancer, gastroesophageal junction adenocarcinoma, malignant pancreatic neoplasm TORL Biotherapeutics, LLC Active not recruiting No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as TORL-2-307-ADC ClinicalTrials.gov intervention name — accepted as the source's own label NCT05156866 ↗
Known as CLDN18.2-307-ADC “A CLDN18.2-directed ADC (CLDN18.2-307-ADC) was also generated by conjugating MMAE to CLDN18.2 mAb using a cleavable linker” PMID 37788341 ↗ Dec 2023
Modality Other / unclassified “antibody drug conjugate” NCT05156866 ↗
Target CLDN18 “A CLDN18.2-directed ADC” PMID 37788341 ↗ Dec 2023